Ameriprise Financial Inc Autolus Therapeutics PLC Transaction History

Ameriprise Financial Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$5.39 - $7.29 $89,969 - $121,684	16,692 New	16,692 $106,000
Q1 2022 May 16, 2022	SELL	$3.52 - $5.46 $76,961 - $119,377	-21,864 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.1 - $7.0 $37,541 - $51,527	7,361 Added 50.76%	21,864 $114,000
Q3 2021 Nov 15, 2021	BUY	$5.32 - $7.37 $77,155 - $106,887	14,503 New	14,503 $95,000

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $272M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.